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This paper describes the application of gene delivery vectors based on connecting together 
two well-defined low-generation poly(L-lysine) (PLL) dendrons using a disulfide-containing 
linker unit. We report that the transfection ability of these vectors in their own right is 
relatively low, because the low-generation number limits the endosomal buffering capacity. 
Importantly, however, we demonstrate that when applied in combination with 
Lipofectamine 2000™, a vector from the cationic lipid family, these small cationic additives 
significantly enhance the levels of gene delivery (up to four-fold). Notably, the cationic 
additives have no effect on the levels of transfection observed with a cationic polymer, such 
as DEAE dextran. We therefore argue that the synergistic effects observed with 
Lipofectamine 2000™ arise as a result of combining the delivery advantages of two different 
classes of vector within a single formulation, with our dendritic additives providing a degree 
of pH buffering within the endosome. As such, the data we present indicate that small 
dendritic structures, although previously largely overlooked for gene delivery owing to their 
inability to transfect in their own right, may actually be useful well-defined additives to well-
established vector systems in order to enhance the gene delivery payload. 
 
Introduction 
The development of effective vectors for the delivery of genetic materials such as DNA 
and/or siRNA into cells is one of the most important targets of medicinal chemists – success 
would have a major impact across a wide range of different diseases.1 Recently, attention 
has begun to increasingly focus on the potential of non-viral vectors in gene delivery,2 in 
particular, because they have the opportunity to avoid problems associated with viral 
vectors such as immunogenicity and other side effects.3 Two classes of vector have seen 
particularly intensive development – cationic polymers4 and cationic lipids.5 Cationic 
polymers achieve DNA binding and delivery owing to their large number of cationic sites 
which can effectively bind polyanionic nucleic acid – however, polycations are known to be 
toxic in vivo, leading to hemolysis and other unwanted side effects. Cationic lipids, on the 
other hand, bind DNA as they assemble multiple positively charged units in a non-covalent 
manner. However, it is important that the payload of genetic material be optimised with 
this class of vector in order to maximise the effect of gene delivery. A number of non-viral 
vectors have been effectively commercialised and have seen widespread in vitro use. As yet, 
however, in spite of extensive work and a number of clinical trials,2 non-viral vectors have 
not yet entered into routine clinical use. In particular, in the process of vector development, 
it is vital to minimise toxicity/immunogenicity and maximise the genetic payload.  
The use of dendritic gene delivery agents has been of considerable interest.6 For 
example, Superfect™ is a fractured poly(amidoamine) (PAMAM) dendrimer developed by 
the groups of Szoka and Tomalia.7Poly(L-lysine) (PLL) dendrimers and dendrons8 have also 
seen considerable development. Niidome and co-workers systematically investigated 
dendritic PLL and reported that high generations (e.g. 5th and 6th generation) were 
required for effective transfection to be observed.9 Park and co-workers have made a 
number of synthetic modifications to lysine-derived dendritic architectures.10 For example, 
they generated ABA-type block co-polymer dendrons in which the A groups were dendritic 
lysine units, whilst the B group was a linker, such as poly(ethylene oxide) (PEG). AB-type 
derivatives have also been investigated in which a dendron based on L-lysine is attached to 
other units. In key work, Florence, Toth and co-workers appended hydrophobic units at the 
focal point, in order to enhance the self-assembly characteristics of the dendritic 
architecture.11 Such structures were tested both in vitro and in vivo and were demonstrated 
to show good levels of transfection. Vlasov and co-workers have also employed hydrophobic 
modifications of dendritic PLL to enhance levels of transfection.12 Cao and co-workers used 
a degradable poly(L-lactide) block as the linker between dendritic units in an ABA structure, 
however, they only applied second-generation lysine units, and the transfection observed 
was therefore only very modest.13 
We have recently been interested in investigating the ability of relatively small and/or 
degradable dendrons to bind DNA and deliver genetic material in vitro.14 We argue that such 
systems should exhibit lower toxicities than their larger polymeric analogues as they will be 
less likely to persist in cells after transfection has taken place. However, in their own right, 
as found in numerous studies, if cationic polymers are too small, they have limited ability to 
transfect, because there are insufficient amine groups to cause pH buffering within the 
endosome – as such, the vector/DNA complex is unable to effectively escape from 
endosomes and gene delivery is ineffective. There have been a handful of reports in which 
cationic lipids have been mixed with cationic polymers giving rise to significant 
enhancements in gene delivery.15 We have therefore become interested in exploring 
synergistic effects using our relatively small dendritic architectures by combining aspects of 
both cationic lipid and cationic polymer characteristics.16 These two main classes of non-
viral vector have different delivery modes within the cell. Cationic lipids can escape from 
endosomesvia lipidic destabilisation of the endosomal membrane,17 whilst cationic 
polymers achieve endosomal rupture by pH-buffering effects.18 We therefore reason that 
these two effects can act in concert to amplify delivery significantly over what might be 
expected based on data from either vector taken individually. 
In this paper we explore the use of small dendritic ABA-type vectors based on dendritic 
PLL connected together using a biodegradable disulfide linkage (Fig. 1). We only investigate 
relatively low-generations of dendrimer in order to minimise toxicity of the polycationic 
surface and to ensure that all of the compounds are well-defined, monodisperse 
architectures, important in biomedical applications. Furthermore, the choice of the disulfide 
linkage should mean that in later in vivo studies, this vector would be expected to break into 
two even smaller, less highly positively charged (and hence less toxic) units.19 It was our 
intention to explore the ability of these small cationic dendrimers to transfect, and in 
particular to determine whether synergistic effects on gene delivery would be observed 
when these vectors were applied together with a well-established cationic lipid or polymer 
vector – commercially available Lipofectamine 2000™ (cationic lipid) and DEAE dextran 
(cationic polymer) were chosen for this study. 
 
  
Fig. 1 Cationic additives for gene delivery 
investigated in this paper. 
 
Results and discussion 
Synthesis of cationic dendrimers 
The syntheses of the vectors used in this study (in Boc-protected form) were previously 
reported and the dendritic materials were applied in materials science.20 The Boc-protecting 
groups were readily removed in quantitative yield by adding trifluoroacetic acid in 
dichloromethane to the dendrimers, which after evaporation of the solvent provided the 
target amine-surfaced cationic dendrimers, G1-SS-G1 and G2-SS-G2, as highly water-soluble 
trifluoroacetate salts (Fig. 1). Compound G0-SS-G0 was commercially available as its 
hydrochloride salt. We then went on to investigate the ability of these dendrimers to bind 
DNA.  
Gel retardation studies 
Gel electrophoresis provides an effective means of investigating the interaction between 
cationic polymers and plasmid DNA. The formation of polyplexes is observed as a reduction 
of mobility of the plasmid DNA (Fig. 2). In these studies, DNA was mixed with increasing 
amounts of polyamine in order to determine the ability of the polyamine to form complexes 
with the DNA. As expected, the G0-SS-G0 model compound (cystamine dihydrochloride) 
failed to show any ability to retard the migration of DNA, even at mass ratios of 1 : 100 
(DNA:amine). This is not surprising given the fact this compound only contains two 
protonatable nitrogen atoms. Normally, tetraamines such as spermine and spermidine are 
required to achieve moderate levels of DNA binding – such systems are present in 
eukaryotic cells where they play an active DNA binding role. In contrast, some retardation 
was observed with tetraamineG1-SS-G1 at reasonably high mass loadings, and this effect 
was enhanced for octaamine G2-SS-G2, which began to retard plasmid DNA even at wt/wt 
ratios as low as 1 : 1 (Fig. 2). However, the levels of binding observed were much lower than 
those previously recorded for our spermine-derived dendrons.14,16 This reflects the expected 
relatively weak DNA binding ability of these low-generation lysine dendrimers.9,13  
 
 
Fig. 2 Agarose gel electrophoresis of plasmid 
DNA (250 ng per lane). Lane 1: Plasmid DNA. 
Lane 2: Plasmid DNA + G0-SS-G0 (250 ng). 
Lane 3: Plasmid DNA + G1-SS-G1 (250 ng). 




Fig. 3 Relative transfection efficiencies of 
lipopolyplexes in (A) C2C12 and (B) MDA-
MB-231 cells. Transfection efficiency was 
measured as luciferase expression 
normalized by total cellular protein (average 
normalized RLU mg−1 of protein), and 
subsequently normalized against the 
transfection efficiency of Lipofectamine 
2000™/DNA complexes to give the relative 
transfection efficiency. (N = 6, error bars 
represent standard deviation). 
 
Gene transfection 
We then investigated the efficacy of the polyamines (G0-SS-G0, G1-SS-G1 and G2-SS-G2) in 
gene delivery to human breast carcinoma cells (MDA-MB-231) and murine myoblasts 
(C2C12). Both cell lines were transfected in vitro with 1 μg of plasmid DNA per 105cells. In 
each case, the DNA was complexed with varying amounts of the different amines. Gene 
transfection efficiency was measured as luciferase enzyme activity and normalized to total 
cell protein.  
Initially, the polyamines were investigated in their own right to determine their ability to 
transfect DNA into cells and allow expression of luciferase, however no measurable 
transfection could be observed in any case. This was not surprising, as the DNA binding of 
these systems was relatively weak, and it was previously known that low-generation lysine-
derived systems were ineffective.9,13 
We have been interested in synergistic effects on gene delivery16 and therefore 
investigated co-formulation of the polyamines with a cationic lipid (Lipofectamine 2000™) 
and a cationic polymer (DEAE dextran). In the case of polymeric DEAE dextran, there was no 
advantage in co-formulating the amines with the polymer:DNA polypoplex. However, on 
mixing the amine with the Lipofectamine 2000™:DNA lipoplex, significant improvements in 
the gene delivery payload were observed. Interestingly all of the amines were observed to 
improve the measurable gene expression over the range of polyamine:Lipofectamine 
2000™:DNA mass ratios investigated (1 : 2.5 : 1, 4 : 2.5 : 1 and 10 : 2.5 : 1), with the general 
trend that the transfection efficiency increased as the quantity of polyamine increased. 
Similar trends were observed for both cell lines, although the transfection into murine 
myoblasts (C2C12) was slightly higher than that for the human breast carcinoma cells (MDA-
MB-231). We argue that the amine additives increase the observed levels of transfection 
because they weakly associate with the DNA lipoplex via electrostatic interactions, but are 
importantly able to assist with the process of lipoplex endosomal escape. It is well known 
that polyamines assist with endosomal escape because of their ability to buffer pH changes, 
leading to endosomal swelling and rupture.18 We propose that this mechanism operates in 
this case, and that the amines therefore have a synergistic effect on the delivery of DNA. 
This proposal is supported by the observation that the presence of the cationic amine 
additive does not enhance the transfection observed with DEAE dextran. This vector is, in its 
own right, a cationic polymer with its own buffering capacity, and would not be expected to 
benefit from the presence of additives capable of performing this role. It was perhaps a bit 
surprising that the number of amines present on the cationic additive appeared to only have 
a limited effect on the transfection enhancement –G1-SS-G1 was only marginally more 
effective than G0-SS-G0, and G2-SS-G2 had lower/similar efficiency. To study this further we 
investigated vector cytotoxicity. 
Cytotoxicity determination 
We determined cytotoxicities of the dendrons using an XTT assay. It is well-known that 
polycationic molecules damage cell membranes as a result of the electrostatic attraction of 
polycations to the plasma membrane. On the other hand, neutral and anionic polymers 
cause minimal damage to cellular membranes. This toxicity of cationic polymers and 
dendrimers has been one of the major drawbacks of their development for in vivogene 
delivery applications. We hypothesised that the low-generation systems employed as 
additives in this work should be relatively non-toxic, and hence their application should 
perhaps be more viable. Human breast carcinoma cells (MDA-MB-231) and murine 
myoblasts (C2C12) were exposed to various conditions (i.e., polyamine, polyamine + DNA, 
polyamine + DNA + Lipofectamine 2000™) for 4 h, and metabolic activity was assayed 20 h 
later. The results of these studies are collected in Table 1.  
Table 1 Cytotoxicity of the polyaminesG0-SS-G0, G1-SS-G1, G2-SS-G2 and 
poly(ethyleneimine) (PEI, 25 kDa) in murine myoblast C2C12 and human breast carcinoma 
MDA-MB-231 cells  
Cell line Conditions 
Metabolic activity (rel. to 1.000) 
G0  G1  G2  PEI  
C2C12 Polyamine alone 0.810 1.091 1.058 0.705 
C2C12 Polyamine + DNA 0.990 1.053 1.047 0.808 
C2C12 Polyamine/DNA + lipofectamine 0.898 0.636 0.714 0.623 
MDA-MB-231  Polyamine alone 1.027 1.037 1.072 0.769 
MDA-MB-231  Polyamine + DNA 0.983 1.153 1.077 0.954 
MDA-MB-231  Polyamine/DNA + lipofectamine 1.274 0.890 0.837 0.423 
 
 
No reduction in metabolic activity was observed when the polyamine alone was added 
at a concentration of 1 μg per 1000 cells. The one exception to this was when a polyamine 
control (25 kDa poly(ethyleneimine), PEI) was employed, in which case the observed 
metabolic activity was reduced by 30% for the C2C12 cells. This is important as it indicates 
that our low-generation dendritic amines are, as anticipated, significantly less cytotoxic 
than a typically employed cationic polymer, PEI. Similarly, when a combination of 
polyamine and DNA was added to the cells (0.2 μg DNA and 1 μg polyamine per 1000 cells), 
our dendrons (G1 and G2) pleasingly had no observable cytotoxicity. Once again, 25 kDa 
PEI reduced metabolic activity, by 20% for the C2C12 cells – demonstrating the greater 
toxicity of larger polymers. 
We then tested cytotoxicity under our transfection conditions (i.e., in the presence of 
lipofectamine 2000™ and DNA). Under these conditions, some toxicity was observed. At a 
relatively high 10:2.5 : 1 mass ratio (0.1 μg polyamine, 0.025 μg Lipofectamine 2000™ and 
0.01 μg DNA per 1000 cells), G1-SS-G1 and G2-SS-G2 caused a reduction in metabolic 
activity of ca. 25–40% in C2C12 cells and 10–20% in MDA-MB-231 cells. The effect of G0-SS-
G0 on metabolic activity was less significant than that of the dendritic analogues – this 
could either be due to its lower cationic character, or more probably because it was used as 
the hydrochloride salt rather than the trifluoroacetate, i.e. the presence of the 
trifluoroacetate counterion may well have led to these observed toxicities.21 We propose 
that the toxicity data may explain why the transfection enhancements observed with G1-
SS-G1 and G2-SS-G2 were perhaps less than might have been expected based on simple 
buffering capacity alone (in comparison with G0-SS-G0) and that toxicity may to some 
extent be limiting the levels of transfection observed with these branched systems. It 
should be noted that these cytotoxicities are measured at relatively high cation loading – 
lower levels can be used for transfection and still give rise to synergistic effects. 
Conclusions 
In conclusion, this study supports the hypothesis that cationic additives can enhance the 
transfection levels observed with cationic lipids. This hybrid vector approach has significant 
potential in enhancing gene delivery payloads. Interestingly, even non-polymeric and low-
generation dendritic cations, which have no transfection effect in their own right, have 
significant positive effects on transfection ability, demonstrating how the advantages of 
cationic ‘polymers’ can be combined with those of cationic lipids. Furthermore, we note 
that the disulfide design of our additives should make them prone to eventual cellular 
degradation,19 breaking them down into smaller units, and potentially limiting longer-term 
toxic effects associated with vector accumulation within transfected cells.22 Further work 
on these vectors would focus on modifying the counter-anion to monitor its effect on 
toxicity, identifying cellular degradation products, as well as testing the transfection 
potential of these hybrid systems under more challenging conditions.  
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